Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer

Kim C. Aalders, Emily L. Postma, Luc J. Strobbe, Margriet van der Heiden-van der Loo, Gabe S. Sonke, Liesbeth J. Boersma, Paul J. van Diest, Sabine Siesling, Thijs van Dalen

Research output: Contribution to journalArticleAcademicpeer-review

21 Citations (Scopus)
43 Downloads (Pure)

Abstract

Purpose: The aim of this study was to evaluate contemporary rates of local recurrence (LR) and regional recurrence (RR) in young patients with breast cancer in relation to tumor biology as expressed by biomarker subtypes.

Patients and Methods: Women < 35 years of age who underwent surgery for primary unilateral invasive breast cancer between 2003 and 2008 were selected from the Netherlands Cancer Registry. Patients were categorized according to biomarker subtypes on the basis of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status. The 5-year risks of developing LR and regional lymph node recurrence were estimated by using Kaplan-Meier statistics.

Results: A total of 1,000 patients were identified, of whom 59% had a known subtype: 39% HR-positive/HER2-negative; 17% HR-positive/HER2-positive; 10% HR-negative/HER2-positive; and 34% HR-negative/HER2-negative (triple negative). Overall 5-year LR and RR rates were 3.5% and 3.7%, respectively. A decreasing trend for both rates was observed over time and was accompanied by a significant decrease in the risk of distant metastases (DM). LR occurred in 4.2%, RR in 6.1%, and DM in 17.8% of patients in 2003, and in 3.2%, 4.4%, and 10.0%, respectively, in 2008. LR and RR rates varied with biomarker subtype. These differences were borderline significant when analyzed for the entire study period (P = .056 and P = .014, respectively) and leveled off after the introduction of trastuzumab after 2005 (P = .24 and P = .42, respectively). Patients with lymph node metastases at the time of diagnosis had an increased risk of RR. The type of surgery performed—breast-conserving or mastectomy—did not influence rates of LR and RR.

Conclusion: Overall, the rates of LR and RR in young patients with early-stage breast cancer were relatively low and varied by biomarker subtype.

Original languageEnglish
Pages (from-to)2107-2114
JournalJournal of clinical oncology
Volume34
Issue number18
DOIs
Publication statusPublished - 2016

Fingerprint

Breast Neoplasms
Recurrence
Hormones
Biomarkers
Neoplasm Metastasis
Lymph Nodes
Netherlands
Registries
Neoplasms
human ERBB2 protein

Keywords

  • METIS-317005
  • IR-100492

Cite this

Aalders, K. C., Postma, E. L., Strobbe, L. J., van der Heiden-van der Loo, M., Sonke, G. S., Boersma, L. J., ... van Dalen, T. (2016). Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer. Journal of clinical oncology, 34(18), 2107-2114. https://doi.org/10.1200/JCO.2015.64.3536
Aalders, Kim C. ; Postma, Emily L. ; Strobbe, Luc J. ; van der Heiden-van der Loo, Margriet ; Sonke, Gabe S. ; Boersma, Liesbeth J. ; van Diest, Paul J. ; Siesling, Sabine ; van Dalen, Thijs. / Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer. In: Journal of clinical oncology. 2016 ; Vol. 34, No. 18. pp. 2107-2114.
@article{2f6a8a1d39704ece8868a068d7fbd5bc,
title = "Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer",
abstract = "Purpose: The aim of this study was to evaluate contemporary rates of local recurrence (LR) and regional recurrence (RR) in young patients with breast cancer in relation to tumor biology as expressed by biomarker subtypes.Patients and Methods: Women < 35 years of age who underwent surgery for primary unilateral invasive breast cancer between 2003 and 2008 were selected from the Netherlands Cancer Registry. Patients were categorized according to biomarker subtypes on the basis of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status. The 5-year risks of developing LR and regional lymph node recurrence were estimated by using Kaplan-Meier statistics.Results: A total of 1,000 patients were identified, of whom 59{\%} had a known subtype: 39{\%} HR-positive/HER2-negative; 17{\%} HR-positive/HER2-positive; 10{\%} HR-negative/HER2-positive; and 34{\%} HR-negative/HER2-negative (triple negative). Overall 5-year LR and RR rates were 3.5{\%} and 3.7{\%}, respectively. A decreasing trend for both rates was observed over time and was accompanied by a significant decrease in the risk of distant metastases (DM). LR occurred in 4.2{\%}, RR in 6.1{\%}, and DM in 17.8{\%} of patients in 2003, and in 3.2{\%}, 4.4{\%}, and 10.0{\%}, respectively, in 2008. LR and RR rates varied with biomarker subtype. These differences were borderline significant when analyzed for the entire study period (P = .056 and P = .014, respectively) and leveled off after the introduction of trastuzumab after 2005 (P = .24 and P = .42, respectively). Patients with lymph node metastases at the time of diagnosis had an increased risk of RR. The type of surgery performed—breast-conserving or mastectomy—did not influence rates of LR and RR.Conclusion: Overall, the rates of LR and RR in young patients with early-stage breast cancer were relatively low and varied by biomarker subtype.",
keywords = "METIS-317005, IR-100492",
author = "Aalders, {Kim C.} and Postma, {Emily L.} and Strobbe, {Luc J.} and {van der Heiden-van der Loo}, Margriet and Sonke, {Gabe S.} and Boersma, {Liesbeth J.} and {van Diest}, {Paul J.} and Sabine Siesling and {van Dalen}, Thijs",
year = "2016",
doi = "10.1200/JCO.2015.64.3536",
language = "English",
volume = "34",
pages = "2107--2114",
journal = "Journal of clinical oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "18",

}

Aalders, KC, Postma, EL, Strobbe, LJ, van der Heiden-van der Loo, M, Sonke, GS, Boersma, LJ, van Diest, PJ, Siesling, S & van Dalen, T 2016, 'Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer', Journal of clinical oncology, vol. 34, no. 18, pp. 2107-2114. https://doi.org/10.1200/JCO.2015.64.3536

Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer. / Aalders, Kim C.; Postma, Emily L.; Strobbe, Luc J.; van der Heiden-van der Loo, Margriet; Sonke, Gabe S.; Boersma, Liesbeth J.; van Diest, Paul J.; Siesling, Sabine; van Dalen, Thijs.

In: Journal of clinical oncology, Vol. 34, No. 18, 2016, p. 2107-2114.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer

AU - Aalders, Kim C.

AU - Postma, Emily L.

AU - Strobbe, Luc J.

AU - van der Heiden-van der Loo, Margriet

AU - Sonke, Gabe S.

AU - Boersma, Liesbeth J.

AU - van Diest, Paul J.

AU - Siesling, Sabine

AU - van Dalen, Thijs

PY - 2016

Y1 - 2016

N2 - Purpose: The aim of this study was to evaluate contemporary rates of local recurrence (LR) and regional recurrence (RR) in young patients with breast cancer in relation to tumor biology as expressed by biomarker subtypes.Patients and Methods: Women < 35 years of age who underwent surgery for primary unilateral invasive breast cancer between 2003 and 2008 were selected from the Netherlands Cancer Registry. Patients were categorized according to biomarker subtypes on the basis of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status. The 5-year risks of developing LR and regional lymph node recurrence were estimated by using Kaplan-Meier statistics.Results: A total of 1,000 patients were identified, of whom 59% had a known subtype: 39% HR-positive/HER2-negative; 17% HR-positive/HER2-positive; 10% HR-negative/HER2-positive; and 34% HR-negative/HER2-negative (triple negative). Overall 5-year LR and RR rates were 3.5% and 3.7%, respectively. A decreasing trend for both rates was observed over time and was accompanied by a significant decrease in the risk of distant metastases (DM). LR occurred in 4.2%, RR in 6.1%, and DM in 17.8% of patients in 2003, and in 3.2%, 4.4%, and 10.0%, respectively, in 2008. LR and RR rates varied with biomarker subtype. These differences were borderline significant when analyzed for the entire study period (P = .056 and P = .014, respectively) and leveled off after the introduction of trastuzumab after 2005 (P = .24 and P = .42, respectively). Patients with lymph node metastases at the time of diagnosis had an increased risk of RR. The type of surgery performed—breast-conserving or mastectomy—did not influence rates of LR and RR.Conclusion: Overall, the rates of LR and RR in young patients with early-stage breast cancer were relatively low and varied by biomarker subtype.

AB - Purpose: The aim of this study was to evaluate contemporary rates of local recurrence (LR) and regional recurrence (RR) in young patients with breast cancer in relation to tumor biology as expressed by biomarker subtypes.Patients and Methods: Women < 35 years of age who underwent surgery for primary unilateral invasive breast cancer between 2003 and 2008 were selected from the Netherlands Cancer Registry. Patients were categorized according to biomarker subtypes on the basis of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status. The 5-year risks of developing LR and regional lymph node recurrence were estimated by using Kaplan-Meier statistics.Results: A total of 1,000 patients were identified, of whom 59% had a known subtype: 39% HR-positive/HER2-negative; 17% HR-positive/HER2-positive; 10% HR-negative/HER2-positive; and 34% HR-negative/HER2-negative (triple negative). Overall 5-year LR and RR rates were 3.5% and 3.7%, respectively. A decreasing trend for both rates was observed over time and was accompanied by a significant decrease in the risk of distant metastases (DM). LR occurred in 4.2%, RR in 6.1%, and DM in 17.8% of patients in 2003, and in 3.2%, 4.4%, and 10.0%, respectively, in 2008. LR and RR rates varied with biomarker subtype. These differences were borderline significant when analyzed for the entire study period (P = .056 and P = .014, respectively) and leveled off after the introduction of trastuzumab after 2005 (P = .24 and P = .42, respectively). Patients with lymph node metastases at the time of diagnosis had an increased risk of RR. The type of surgery performed—breast-conserving or mastectomy—did not influence rates of LR and RR.Conclusion: Overall, the rates of LR and RR in young patients with early-stage breast cancer were relatively low and varied by biomarker subtype.

KW - METIS-317005

KW - IR-100492

U2 - 10.1200/JCO.2015.64.3536

DO - 10.1200/JCO.2015.64.3536

M3 - Article

VL - 34

SP - 2107

EP - 2114

JO - Journal of clinical oncology

JF - Journal of clinical oncology

SN - 0732-183X

IS - 18

ER -

Aalders KC, Postma EL, Strobbe LJ, van der Heiden-van der Loo M, Sonke GS, Boersma LJ et al. Contemporary Locoregional Recurrence Rates in Young Patients With Early-Stage Breast Cancer. Journal of clinical oncology. 2016;34(18):2107-2114. https://doi.org/10.1200/JCO.2015.64.3536